2006 proposed fee schedule - American Society of Clinical Oncology

234
allowable for dispensing inhalation drugs, furnishing blood
clotting factor, and supplying certain other Part B drugs.
This section of the preamble also discusses proposed changes
in how manufacturers calculate and report ASP data to us.
1. ASP Issues
[If you choose to comment on issues in this section, please
include the caption “ASP Issues” at the beginning of your
comments.]
Section 303(c) of the MMA amended Title XVIII of the
Act by adding new section 1847A. This new section
establishes the use of the ASP methodology for payment for
most drugs and biologicals not paid on a cost or prospective
payment basis furnished on or after January 1, 2005. The
ASP reporting requirements are set forth in section 1927(b)
of the Act. Manufacturers must submit ASP data to us
quarterly. The manufacturers’ submissions are due to us not
later than 30 days after the last day of each calendar
quarter. The methodology for developing Medicare drug
payment allowances based on the manufacturers’ submitted ASP
data is specified in the regulations in part 414, subpart K.
Based on the data we receive, we update the Part B drug
payment amounts quarterly.
In this section of the preamble, we discuss issues and
propose changes related to the methodology manufacturers use
to apply the estimate of lagged price concessions in the ASP